-
.
- In November 2022, Rubius Therapies Inc RUBY launched a procedure to check out a variety of tactical options and also intended to involve a financial investment financial institution to function as a tactical expert.
- .(* )The biotech stated its board accepted the strategy with an unique conference of Rubius’ shareholders being aligned to look for a thumbs-up, per an
- .(* )The biotech ended its scientific tests and also release greater than 80% of the personnel so the continuing to be workers might carry out a different course. SEC .
- .
- .
- .
- RUBY shares are down 13.949% at $0.1420 on the last check Wednesday.
- © 2023 Benzinga.com. Benzinga does not give financial investment guidance. All civil liberties scheduled.
.(* )However the damaged firm fell short to discover any kind of options, and also the firm’s board accepted a strategy of liquidation and also dissolution.
declaring.
In September, Rubius Rehab introduced strategies to restructure and also straighten sources to progress its next-generation red blood cell-based cell conjugation system.
It terminated Stage 1 tests of RTX-240 and also RTX-224 for sophisticated strong lumps and also given up 75% of its workers.
Rubius went public in July 2018 with a market cap of around $2 billion.
Rate Activity:
.
